Cyclin Dependent Kinase 7 - Pipeline Review, H2 2019
Cyclin Dependent Kinase 7 - Pipeline Review, H2 2019
SUMMARY
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Cell division protein kinase 7 is an enzyme that in humans is encoded by the CDK7 gene. CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. It phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation. thus regulating cell cycle progression. Upon DNA damage it triggers p53/TP53 activation by phosphorylation but is inactivated in turn by p53/TP53. This feedback loop leads to an arrest of the cell cycle.
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 5, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders and Respiratory which include indications Colorectal Cancer, Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Anaplastic Astrocytoma, Colon Cancer, Cystic Fibrosis, Cytomegalovirus (HHV-5) Infections, Gastric Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Inflammation, Liver Cancer, Malignant Pleural Mesothelioma, Metastatic Hepatocellular Carcinoma (HCC), Multiple Myeloma (Kahler Disease), Pediatric Diffuse Intrinsic Pontine Glioma, Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Rheumatoid Arthritis, Sarcomas and Thymic Carcinoma.
The latest report Cyclin Dependent Kinase 7 - Pipeline Review, H2 2019, outlays comprehensive information on the Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Cell division protein kinase 7 is an enzyme that in humans is encoded by the CDK7 gene. CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. It phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation. thus regulating cell cycle progression. Upon DNA damage it triggers p53/TP53 activation by phosphorylation but is inactivated in turn by p53/TP53. This feedback loop leads to an arrest of the cell cycle.
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 5, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders and Respiratory which include indications Colorectal Cancer, Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Anaplastic Astrocytoma, Colon Cancer, Cystic Fibrosis, Cytomegalovirus (HHV-5) Infections, Gastric Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Inflammation, Liver Cancer, Malignant Pleural Mesothelioma, Metastatic Hepatocellular Carcinoma (HCC), Multiple Myeloma (Kahler Disease), Pediatric Diffuse Intrinsic Pontine Glioma, Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Rheumatoid Arthritis, Sarcomas and Thymic Carcinoma.
The latest report Cyclin Dependent Kinase 7 - Pipeline Review, H2 2019, outlays comprehensive information on the Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23)
- The report reviews Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Overview
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Companies Involved in Therapeutics Development
Adastra Pharmaceuticals Inc
Aurigene Discovery Technologies Ltd
Beta Pharma Inc
Carrick Therapeutics UK Ltd
Cyclacel Pharmaceuticals Inc
Qurient Co Ltd
Syros Pharmaceuticals Inc
Tiziana Life Sciences Plc
Ube Industries Ltd
Yungjin Pharm Co Ltd
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Drug Profiles
BS-181L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-7001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapacitabine + seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK7 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK7 for Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Solid Tumor, Inflammation and Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SY-5609 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UD-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YPN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zotiraciclib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Dormant Products
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Discontinued Products
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Product Development Milestones
Featured News & Press Releases
Oct 29, 2019: Syros presents new preclinical data on SY-5609, its highly selective oral CDK7 inhibitor, at AACR-NCI-EORTC International Conference
Oct 17, 2019: Syros announces update on oral CDK7 inhibitor SY-5609
Sep 04, 2019: Tiziana Life Sciences -phase 2a clinical data
Sep 04, 2019: Adastra Pharmaceuticals to present at the 2019 Janney Healthcare Conference
Aug 01, 2019: Syros highlights key accomplishments and provides milestone update on SY-5609
Jul 24, 2019: Tiziana reveals positive results for Milciclib in liver cancer trial
Jul 22, 2019: Tiziana reports phase 2a clinical data with milciclib monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
Jun 03, 2019: Adastra Pharmaceuticals announces positive interim data from Phase 1b clinical trial of zotiraciclib in the treatment of recurrent malignant gliomas
May 16, 2019: Adastra Pharmaceuticals announces that data from phase 1b clinical trial of Zotiraciclib will be presented at ASCO 2019
Apr 24, 2019: Tiziana reports encouraging interim clinical data from an ongoing phase 2a trial with milciclib in advanced liver cancer patients
Apr 17, 2019: Syros to host key opinion leader symposium on CDK7 Inhibitor SY-5609 on April 24, 2019
Apr 09, 2019: Yungjin Pharm announced a new targeted anti-cancer drug at AACR 2019
Apr 02, 2019: Syros presents preclinical data on SY-5609 at AACR 2019 annual meeting
Feb 27, 2019: Syros to present new preclinical data on its Selective CDK7 inhibitor SY-5609 at AACR Annual Meeting
Jan 06, 2019: Syros provides update on its oncology drug candidate SY-5609
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Overview
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Companies Involved in Therapeutics Development
Adastra Pharmaceuticals Inc
Aurigene Discovery Technologies Ltd
Beta Pharma Inc
Carrick Therapeutics UK Ltd
Cyclacel Pharmaceuticals Inc
Qurient Co Ltd
Syros Pharmaceuticals Inc
Tiziana Life Sciences Plc
Ube Industries Ltd
Yungjin Pharm Co Ltd
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Drug Profiles
BS-181L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-7001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapacitabine + seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK7 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK7 for Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Solid Tumor, Inflammation and Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SY-5609 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UD-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YPN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zotiraciclib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Dormant Products
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Discontinued Products
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Product Development Milestones
Featured News & Press Releases
Oct 29, 2019: Syros presents new preclinical data on SY-5609, its highly selective oral CDK7 inhibitor, at AACR-NCI-EORTC International Conference
Oct 17, 2019: Syros announces update on oral CDK7 inhibitor SY-5609
Sep 04, 2019: Tiziana Life Sciences -phase 2a clinical data
Sep 04, 2019: Adastra Pharmaceuticals to present at the 2019 Janney Healthcare Conference
Aug 01, 2019: Syros highlights key accomplishments and provides milestone update on SY-5609
Jul 24, 2019: Tiziana reveals positive results for Milciclib in liver cancer trial
Jul 22, 2019: Tiziana reports phase 2a clinical data with milciclib monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
Jun 03, 2019: Adastra Pharmaceuticals announces positive interim data from Phase 1b clinical trial of zotiraciclib in the treatment of recurrent malignant gliomas
May 16, 2019: Adastra Pharmaceuticals announces that data from phase 1b clinical trial of Zotiraciclib will be presented at ASCO 2019
Apr 24, 2019: Tiziana reports encouraging interim clinical data from an ongoing phase 2a trial with milciclib in advanced liver cancer patients
Apr 17, 2019: Syros to host key opinion leader symposium on CDK7 Inhibitor SY-5609 on April 24, 2019
Apr 09, 2019: Yungjin Pharm announced a new targeted anti-cancer drug at AACR 2019
Apr 02, 2019: Syros presents preclinical data on SY-5609 at AACR 2019 annual meeting
Feb 27, 2019: Syros to present new preclinical data on its Selective CDK7 inhibitor SY-5609 at AACR Annual Meeting
Jan 06, 2019: Syros provides update on its oncology drug candidate SY-5609
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Adastra Pharmaceuticals Inc, H2 2019
Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Pipeline by Beta Pharma Inc, H2 2019
Pipeline by Carrick Therapeutics UK Ltd, H2 2019
Pipeline by Cyclacel Pharmaceuticals Inc, H2 2019
Pipeline by Qurient Co Ltd, H2 2019
Pipeline by Syros Pharmaceuticals Inc, H2 2019
Pipeline by Tiziana Life Sciences Plc, H2 2019
Pipeline by Ube Industries Ltd, H2 2019
Pipeline by Yungjin Pharm Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Adastra Pharmaceuticals Inc, H2 2019
Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Pipeline by Beta Pharma Inc, H2 2019
Pipeline by Carrick Therapeutics UK Ltd, H2 2019
Pipeline by Cyclacel Pharmaceuticals Inc, H2 2019
Pipeline by Qurient Co Ltd, H2 2019
Pipeline by Syros Pharmaceuticals Inc, H2 2019
Pipeline by Tiziana Life Sciences Plc, H2 2019
Pipeline by Ube Industries Ltd, H2 2019
Pipeline by Yungjin Pharm Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
Adastra Pharmaceuticals Inc
Aurigene Discovery Technologies Ltd
Beta Pharma Inc
Carrick Therapeutics UK Ltd
Cyclacel Pharmaceuticals Inc
Qurient Co Ltd
Syros Pharmaceuticals Inc
Tiziana Life Sciences Plc
Ube Industries Ltd
Yungjin Pharm Co Ltd
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
Adastra Pharmaceuticals Inc
Aurigene Discovery Technologies Ltd
Beta Pharma Inc
Carrick Therapeutics UK Ltd
Cyclacel Pharmaceuticals Inc
Qurient Co Ltd
Syros Pharmaceuticals Inc
Tiziana Life Sciences Plc
Ube Industries Ltd
Yungjin Pharm Co Ltd
